Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Visudyne teraphy may play a new role in AMD treatment

April 7, 2008

Positive Results From Visudyne (R) Combination Therapy Study Reported at Annual Macula Society Conference | www.pipelinereview.com

1. AMD 2. Anti VEG 3. Visudyne

New molecule for the treatment of rheumatoid arthritis with minor toxicity.

March 5, 2008

Glenmark’s molecule for Rheumatoid Arthritis - GRC 4039 | www.pipelinereview.com

1. Rheumatoid arthritis as an invalidating disease (1% population). 2. Anti TNF-α agents. 3. Clinical trial for inflammatory disorders by Glenmark.

Decreasing the risk of complications in the treatment of wet AMD.

March 5, 2008

MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration | pharmalive.com

1. Wet AMD. 2. Macular edema. 3. Intravitreal injection.

Choosing the best treatment for wet AMD.

March 5, 2008

Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com

1. Lucentis. 2. Avastin. 3. Cost.

Keeping the privacy of health data.

March 5, 2008

Google to store patients' health records | news.yahoo.com

1. Internet. 2. Medical records. 3. Privacy.

New promising agent for glaucoma treatment

February 19, 2008

Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com

1. Glaucoma therapy 2. IOP reduction 3. Combined therapy

New promising glaucoma agent for glaucoma treatment

February 18, 2008

Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com

1. glaucoma treatment 2. combined therapy 3. IOP reduction

Eyelid basal cell carcinoma

August 13, 2007

Basal Cell Carcinoma of the Eyelids | www.medscape.com

1. Eyelid basal cell carcinoma. 2. Health problem. 3. Early diagnostic and correct surgery treatment. 4. Risk factors and prevention.

Bimatoprost is known to be slighatly more potent that prostaglandin

August 10, 2007

Bimatoprost May Provide Better Intraocular Pressure Control Than Latanoprost | www.medscape.com

1. Exfoliative glaucoma is specillay difficult to treat medically. 2. Prostaglandin. 3. Early surgery. 4. Lesser costs.

CVS/Pharmacy stores for medical basic assistence.

July 26, 2007

An Innovation in Health Care Opens at CVS/Pharmacy Stores in Knoxville and Chattanooga | money.cnn.com

1. Medical asistance. 2. Health unexpensiveness. 3. Posibility of multiple medical offices. 4. Quality of services.

Page : 11 to 10 of 10

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

This author consults with leading institutions through GLG

Most Popular Healthcare News